Selank: Tuftsin-Derived Neuropeptide in Anxiolytic and Cognitive Research

What Is Selank?

Selank is a synthetic heptapeptide (7 amino acids) designed as a stabilized analog of tuftsin — an endogenous tetrapeptide (Thr-Lys-Pro-Arg) found as a fragment of the Fc region of IgG immunoglobulin. Selank's sequence extends the tuftsin core with a Pro-Gly-Pro tripeptide tail: Thr-Lys-Pro-Arg-Pro-Gly-Pro

The Pro-Gly-Pro extension was added by researchers at the Institute of Molecular Genetics and Institute of Bioorganic Chemistry in Moscow to improve metabolic stability — tuftsin itself is rapidly degraded by serum enzymes, making it unsuitable for most pharmacological research. The addition of the tail extends Selank's plasma half-life while preserving (and in some ways enhancing) tuftsin's immunomodulatory activity.

Selank has been studied clinically in Russia for generalized anxiety disorder indications and appears in several published Russian clinical trials. Its regulatory status outside Russia is limited to research contexts.

Discovery and Development Context

Selank emerged from the same Soviet-era research program that produced Semax. The two peptides represent complementary research strategies: while Semax was developed to capture the cognitive-stimulating and neuroprotective properties of ACTH fragments, Selank was developed to capture the anxiolytic and immunomodulatory properties of tuftsin in a metabolically stable form.

The decision to extend tuftsin (Thr-Lys-Pro-Arg) with Pro-Gly-Pro followed from the observation that this tripeptide "carrier" sequence, common in the Russian neuropeptide research tradition, provided enzymatic resistance at the C-terminus — the primary degradation point for the native tetrapeptide.

Mechanism of Action

Selank's pharmacological activity involves several pathways:

GABAergic system modulation

Selank has been reported to potentiate GABA-A receptor activity in electrophysiological recordings from hippocampal and cortical preparations. This mechanism — similar in concept to benzodiazepines but through a different allosteric site — produces anxiolytic-profile effects in animal behavioral models without the characteristic dependence liability, tolerance, or sedation seen with classical benzodiazepine GABA-A modulators.

The specific binding site and allosteric mechanism of Selank at GABA-A receptors is not fully characterized at the molecular level; this remains an active area of pharmacological investigation.

BDNF modulation

Published research reports that Selank administration in animal models increases BDNF (brain-derived neurotrophic factor) expression in hippocampal and frontal cortical regions — an effect also seen with Semax, though through a different primary mechanism. BDNF elevation is associated with synaptic plasticity, neuronal survival, and cognitive function in the published literature.

The magnitude of BDNF effect reported for Selank in published animal studies is generally smaller than that reported for Semax, consistent with the two compounds' different primary receptor profiles.

Enkephalinase inhibition

Selank has been reported to inhibit enkephalinase (neutral endopeptidase, neprilysin) — the enzyme responsible for degrading endogenous enkephalins. By slowing enkephalin degradation, Selank may prolong the activity of endogenous opioid peptides involved in pain modulation and mood regulation. This mechanism is shared with Semax and may contribute to some of the behavioral effects seen with both peptides.

Immunomodulatory activity (tuftsin-derived)

Tuftsin is a known immunostimulatory peptide that activates macrophage function and natural killer (NK) cell activity. Selank retains some of this tuftsin-derived immunomodulatory activity in published ex vivo studies, with reported effects on cytokine expression profiles in immune cell models. This component distinguishes Selank's pharmacological profile from typical anxiolytic compounds.

Research Applications

Anxiolytic-profile behavioral studies

The strongest evidence base for Selank comes from animal behavioral pharmacology:

Reduction of anxiety-like behavior in elevated plus maze, open field, and light/dark box tests in rodents
Effects comparable to reference anxiolytics in some assays, without the motor impairment or sedation associated with benzodiazepines
No evidence of tolerance development in repeated-dose animal studies

These findings make Selank a useful research tool for studying non-benzodiazepine anxiolytic mechanisms in preclinical models.

Cognitive function models

In both animal and limited human research, Selank has been reported to produce mild cognitive-facilitating effects — particularly in attention and working memory tasks. The magnitude is generally smaller than Semax in direct comparisons; the mechanism is hypothesized to be mediated more by anxiolytic normalization of stress-induced cognitive impairment than by direct neurotrophic effects.

Stress response research

Multiple published animal studies have examined Selank in models of acute and chronic stress. Reported effects include modulation of corticosterone responses and normalization of stress-induced changes in brain monoamine levels. These findings suggest a role for Selank in studies examining peptidergic modulation of the stress axis.

Selank vs Semax: Complementary Research Profiles

Property

Selank

Semax

Parent peptide	Tuftsin	ACTH(4-10)
Primary receptor mechanism	GABA-A modulation	Melanocortin receptors + BDNF
Behavioral profile	Anxiolytic-dominant	Activating/stimulating-dominant
BDNF effect (published)	Moderate	Strong
Immune effects	Yes (tuftsin component)	Minimal
Half-life (intranasal)	~10 minutes	~7 minutes

The complementary profiles of Selank and Semax — one anxiolytic-dominant, one activating-dominant — explain why the two are frequently studied together or in alternation in research protocols targeting broad neuropeptide coverage. See our Semax research primer for detailed mechanism coverage of the companion compound.

Dose Forms and Handling

Selank is supplied as a lyophilized powder. The short plasma half-life (~10 minutes, intranasal) reflects rapid enzymatic degradation in biological fluids, so handling and timing in experimental protocols should account for this.

Storage (lyophilized): −20 °C; stable for 12–24 months
Storage (reconstituted): 2–8 °C; use within 2–4 weeks; aliquot and freeze for longer storage

See our reconstitution guide and storage guide.

Product Availability

Phase 1 Peptides stocks Selank at 99%+ purity with third-party laboratory documentation:

Selank — research-grade, multiple dose sizes

Summary

Selank is a synthetic tuftsin analog designed for metabolic stability, with a pharmacological profile characterized by GABA-A receptor modulation, moderate BDNF upregulation, and retained tuftsin-derived immunostimulatory activity. Its primary research application is in anxiolytic-profile behavioral pharmacology, where it provides a non-benzodiazepine reference point. It is frequently studied alongside Semax due to their complementary activating vs. anxiolytic profiles, together providing broader neuropeptide pathway coverage in cognitive and stress-response research.

For a three-way comparison of Semax, Selank, and DSIP as neuropeptide research tools, see the Neuropeptide Research overview.

How does Selank's mechanism differ from classical benzodiazepine anxiolytics in published research?

Selank is reported to potentiate GABA-A receptor activity through a distinct allosteric mechanism from benzodiazepines. In animal models, Selank produces anxiolytic-profile behavioral effects — reduced anxiety-like behavior in elevated plus maze and open field tests — without the motor impairment, sedation, or tolerance development associated with benzodiazepine GABA-A modulators. This non-benzodiazepine profile makes Selank a useful tool for studying alternative anxiolytic mechanisms in preclinical models.

What is Selank's relationship to tuftsin, and why was the Pro-Gly-Pro tail added?

Selank is a synthetic analog of tuftsin — an endogenous tetrapeptide (Thr-Lys-Pro-Arg) found as a fragment of IgG — extended with a Pro-Gly-Pro C-terminal sequence. The extension was designed to improve metabolic stability: native tuftsin is rapidly degraded by serum enzymes, limiting its research utility. The Pro-Gly-Pro tail provides enzymatic resistance at the primary degradation site while preserving and in some cases enhancing tuftsin's pharmacological activity.

How do Selank's BDNF effects compare to those reported for Semax in published literature?

Both Selank and Semax upregulate BDNF in hippocampal and cortical tissue in animal studies, but the magnitude differs. Semax studies consistently report stronger BDNF elevation as a primary mechanism. Selank's BDNF effect is considered secondary to its GABAergic modulation, and the magnitude in published comparisons is generally smaller. The complementary profiles — Semax's stronger neurotrophic and dopaminergic activity vs. Selank's anxiolytic GABAergic profile — explain why the two are frequently studied together.

What immunomodulatory properties does Selank retain from its tuftsin origin?

Tuftsin is a known immunostimulatory peptide that activates macrophage function and natural killer cell activity. Published ex vivo studies report that Selank retains some of this tuftsin-derived immunomodulatory activity, with effects on cytokine expression profiles in immune cell models. This immune component distinguishes Selank's pharmacological profile from typical anxiolytic compounds studied in behavioral pharmacology.